Final OS analyses from the TOURMALINE- MM3 and -MM4 RCTs of ixazomib maintenance in newly diagnosed multiple myeloma - Poll - MDSpire

Final OS analyses from the TOURMALINE- MM3 and -MM4 RCTs of ixazomib maintenance in newly diagnosed multiple myeloma

  • By

  • Meletios A. Dimopoulos

  • Sagar Lonial

  • Wee-Joo Chng

  • Shinsuke Iida

  • María-Victoria Mateos

  • Gareth J. Morgan

  • Cong Li

  • Catriona Byrne

  • Kaveri Suryanarayan

  • Richard Labotka

  • S. Vincent Rajkumar

  • December 4, 2025

  • 0 min

Share

Original Source(s)

Final OS analyses from the TOURMALINE- MM3 and -MM4 RCTs of ixazomib maintenance in newly diagnosed multiple myeloma

  • by Meletios A. Dimopoulos, Sagar Lonial, Wee-Joo Chng, Shinsuke Iida, María-Victoria Mateos, Gareth J. Morgan, Cong Li, Catriona Byrne, Kaveri Suryanarayan, Richard Labotka, S. Vincent Rajkumar

  • December 4, 2025

Related Content

Assessment of the Safety and Effectiveness of CD38-Targeted CAR-T Cell Therapy in Treating Multiple Myeloma: A Systematic Review and Meta-Analysis

CRISPR Enables In Vivo CAR T Cell Production

In vivo gene editing strategy generates CAR T cells directly inside the body – sidestepping costly manufacturing

  • March 30, 2026

  • 2 min
Targeting CD38 Enzymatic Function in Antibody-Driven Immunotherapy for Multiple Myeloma: Insights from Basic Research